Jérôme R Lechien1,2,3,4, Alexandra Rodriguez Ruiz1,3, Didier Dequanter1,3, Francois Bobin1,5, Francois Mouawad6, Vinciane Muls1,7, Kathy Huet1,4, Bernard Harmegnies1,4, Sarah Remacle8, Camille Finck1,8, Sven Saussez1,2,3. 1. Research Committee of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS). 2. Laboratory of Anatomy and Cell Biology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. 3. Department of Otorhinolaryngology and Head and Neck Surgery, CHU Saint-Pierre, Brussels, Belgium. 4. Laboratory of Phonetics, Faculty of Psychology, Research Institute for Language sciences and Technology, University of Mons (UMons), Mons, Belgium. 5. Department of Otorhinolaryngology and Head and Neck Surgery, Elsan Polyclinique de Poitiers, France. 6. Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Lille, Lille, France. 7. Department of Gastroenterology and Endoscopy, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium. 8. Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Liège (Sart Tilman), Liège, Belgium.
Abstract
OBJECTIVE: To develop and validate the Reflux Sign Assessment (RSA), a clinical instrument evaluating the physical findings of laryngopharyngeal reflux (LPR). METHODS: A total of 106 patients completed a 3-month treatment based on the association of diet, pantoprazole, alginate, or magaldrate with the LPR characteristics (acid, nonacid, mixed). Forty-two asymptomatic individuals completed the study (control group). The RSA results and reflux finding score (RFS) were documented for the LPR patients at baseline and after treatment. Intrarater reliability was assessed through a test-retest blinded evaluation of signs (7-day intervals). Interrater reliability was assessed by comparing the RSA evaluations of three blinded otolaryngologists through Kendall's W. Responsiveness to change was evaluated through a comparison of the baseline and 3-month posttreatment findings. The RSA cutoffs for determining the presence and absence of LPR were examined by receiver operating characteristic (ROC) analysis. RESULTS: A total of 102 LPR patients completed the study (68 females). The mean age was 53 years. The mean RSA at baseline was 25.95 ± 9.58; it significantly improved to 18.96 ± 7.58 after 3 months of therapy (P < .001). RSA exhibited good intra- (r = 0.813) and interrater (Kendall's W = 0.663) reliabilities (N = 56). There was no significant association between the RSA, gastrointestinal endoscopy findings, and the types of reflux (acid, nonacid, or mixed) according to impedance-pH monitoring. An RSA >14 may be suggestive of LPR. CONCLUSION: The RSA is a complete clinical instrument evaluating both laryngeal and extralaryngeal findings associated with LPR. The RSA demonstrated high intra- and interrater reliabilities and responsiveness to change.
OBJECTIVE: To develop and validate the Reflux Sign Assessment (RSA), a clinical instrument evaluating the physical findings of laryngopharyngeal reflux (LPR). METHODS: A total of 106 patients completed a 3-month treatment based on the association of diet, pantoprazole, alginate, or magaldrate with the LPR characteristics (acid, nonacid, mixed). Forty-two asymptomatic individuals completed the study (control group). The RSA results and reflux finding score (RFS) were documented for the LPR patients at baseline and after treatment. Intrarater reliability was assessed through a test-retest blinded evaluation of signs (7-day intervals). Interrater reliability was assessed by comparing the RSA evaluations of three blinded otolaryngologists through Kendall's W. Responsiveness to change was evaluated through a comparison of the baseline and 3-month posttreatment findings. The RSA cutoffs for determining the presence and absence of LPR were examined by receiver operating characteristic (ROC) analysis. RESULTS: A total of 102 LPR patients completed the study (68 females). The mean age was 53 years. The mean RSA at baseline was 25.95 ± 9.58; it significantly improved to 18.96 ± 7.58 after 3 months of therapy (P < .001). RSA exhibited good intra- (r = 0.813) and interrater (Kendall's W = 0.663) reliabilities (N = 56). There was no significant association between the RSA, gastrointestinal endoscopy findings, and the types of reflux (acid, nonacid, or mixed) according to impedance-pH monitoring. An RSA >14 may be suggestive of LPR. CONCLUSION: The RSA is a complete clinical instrument evaluating both laryngeal and extralaryngeal findings associated with LPR. The RSA demonstrated high intra- and interrater reliabilities and responsiveness to change.
Authors: Lee M Akst; Jonathan M Bock; Jerome R Lechien; Thomas L Carroll; Jacqueline E Allen; Tareck Ayad; Necati Enver; Young-Gyu Eun; Paulo S Perazzo; Fabio Pupo Ceccon; Geraldo D Sant'Anna; Rui Imamura; Sampath Kumar Raghunandhan; Carlos M Chiesa-Estomba; Christian Calvo-Henriquez; Sven Saussez; Petros D Karkos; Marc Remacle Journal: Eur Arch Otorhinolaryngol Date: 2021-02-27 Impact factor: 2.503
Authors: Jerome R Lechien; Anaïs Rameau; Lisa G De Marrez; Gautier Le Bosse; Karina Negro; Andra Sebestyen; Robin Baudouin; Sven Saussez; Stéphane Hans Journal: Eur Arch Otorhinolaryngol Date: 2022-06-28 Impact factor: 2.503
Authors: Afrin N Kamal; Shumon I Dhar; Thomas L Carroll; Lee M Akst; Jonathan M Bock; John O Clarke; Jerome R Lechien; Jacqueline Allen; Peter C Belafsky; Joel H Blumin; Walter W Chan; Ronnie Fass; P Marco Fisichella; Michael Marohn; Ashli K O'Rourke; Gregory Postma; Edoardo V Savarino; Michael F Vaezi Journal: Dig Dis Sci Date: 2022-08-22 Impact factor: 3.487
Authors: Jerome R Lechien; Sven Saussez; Vinciane Muls; Maria R Barillari; Carlos M Chiesa-Estomba; Stéphane Hans; Petros D Karkos Journal: J Clin Med Date: 2020-11-10 Impact factor: 4.241
Authors: Jerome R Lechien; Stéphane Hans; Francois Bobin; Christian Calvo-Henriquez; Sven Saussez; Petros D Karkos Journal: J Clin Med Date: 2021-05-31 Impact factor: 4.241
Authors: E Wlodarczyk; A Domeracka-Kolodziej; B Miaskiewicz; H Skarzynski; P H Skarzynski Journal: Eur Arch Otorhinolaryngol Date: 2021-08-06 Impact factor: 2.503